Clinical Trial Update: Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether adding laser photocoagulation to ranibizumab reduces injection frequency without sacrificing efficacy or safety in macular edem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema Secondary to Branch Retinal Vein Occlusion

Drugs mentioned

• Laser photocoagulation (laser photocoagulation)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) | Phase 4 | Status: COMPLETED | Results posted: 2020-02-25